← All trials
NCT04163588
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2019
- Primary completion
- Oct 31, 2020
- Completion date
- Dec 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 310
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Policlinico CasilinoLead sponsor
- Policlinico CasilinoReponsible party - principal investigator
- Vita-Salute University of Milano. ItalyCollaborator
- University of Roma La SapienzaCollaborator
- Policlinico CasilinoOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.